Exome Asset Management Shortlisted for HFM’s Sector Specialist and Emerging Market Fund Awards

NEW YORK--(BUSINESS WIRE)--Exome Asset Management (“Exome”), an innovative asset management company focusing on investing in public markets across the worldwide healthcare industry, today announced it has been shortlisted for the HFM US Performance Awards 2022 for both Sector Specialist and Emerging Market Fund.

The HFM US Performance Awards are one of the most important and influential awards in the US hedge fund calendar. The awards recognize hedge fund, CTA and fund of hedge fund performance, encompassing the whole breadth of hedge fund strategy, from credit and equity to macro and managed futures. Judging is conducted by a panel of leading institutional and private investors and investment consultants who take account of risk-adjusted performance, AUM and any professional knowledge about the fund.

“We are very excited to be shortlisted once again for the HFM US Performance Awards,” said Sam Isaly, Managing Partner and Founder of Exome Asset Management. “We have been laser focused on adapting to the rapid changes and technological advances in the healthcare industry over the past few years, and this honor is a testament to our firm’s strong ability to select what we believe to be the best and most innovative healthcare investments across all sectors, globally.”

The HFM US Performance Awards ceremony will take place on October 18, 2022 at Capitale in New York City.

Exome practices two active investment strategies: one which invests broadly across worldwide healthcare subsectors and geographies, and another that specializes in healthcare with an emphasis on public company opportunities in emerging markets. The firm holds both long and short positions in companies that are broadly diversified by geography and healthcare subsector.

About Exome Asset Management
Exome Asset Management is an innovative asset management company focusing on investing in public markets across the worldwide healthcare industry, including pharmaceuticals, biotechnology, healthcare services, and medical devices. Exome employs sound investment strategies and a philosophy developed by Sam Isaly, who has spent the majority of his 45-year career focused on both developed and emerging markets healthcare. For more information, please visit www.exomeasset.com.